logo
  • About Initiator Pharma
    • Mission
    • Scientific and Clinical Advisory Board
    • Goals, strategy and business model
    • CEO Letter
    • History
  • Science
    • Pipeline
    • Pudafensine
      • Clinical programs
        • IPED2015 – Organic Erectile dysfunction
        • IPTN2021 – Neuropathic Pain
      • Preclinical program
        • IPFSD2023 – Female Sexual Dysfunction
    • IP2018
      • Clinical programs
        • IP2018 – Psychogenic Erectile dysfunction
      • Preclinical program
        • IPFSD2023 – Female Sexual Dysfunction
    • Therapeutic Areas
      • Erectile Dysfunction
      • Female Sexual Dysfunction
      • Depression
      • Trigeminal Neuralgia
  • Governance
    • General Meetings
    • Management
    • Board of Directors
    • Auditing
    • Articles of Association
    • Remuneration and incentive program
  • Investors
    • Investment case
    • Financial Reports
    • The Share
    • Ownership Structure
    • Analyst and Media Coverage
    • Financial Calendar
    • Prospectuses
    • Press Releases
    • Subscribe
    • Certified Adviser
  • Media
    • Press Releases
    • Event Calendar
    • Subscribe
  • Contact
Loading..

Investors

Press releases

  • Regulatory May 7, 2025 English
    Initiator Pharma A/S calls for the Annual General Meeting 2025
  • Non Regulatory May 7, 2025 English
    Remuneration report 2024 for Initiator Pharma A/S
  • Regulatory April 30, 2025 English
    Annual report 2024 for Initiator Pharma A/S
Older releases

Latest reports

  • Regulatory April 30, 2025 English
    Annual report 2024 for Initiator Pharma A/S
  • Regulatory February 28, 2025 English
    INITIATOR PHARMA: YEAR END REPORT 2024
  • Regulatory November 29, 2024 English
    INITIATOR PHARMA: Q3 2024 REPORT
All reports

Calendar

  • May 9, 2025
    Interim Report Q1 2025
    Add to calendar
  • May 23, 2025
    Annual General Meeting 2025
    Add to calendar
All events

Investor contact

IR Contact
IR Contact
Torgeir Vaage
[email protected]

Subscribe via e-mail

Initiator Pharma Numbers

  • Expected Number of men affected by Erectile Dysfunction worldwide by 2025 322 million
  • Number of people worldwide that are diagnosed with Trigeminal Neuralgia every year: 15000
  • Men with Erectile Dysfunction who do not respond to drug therapy 40 %
  • Investors
    • Investment case
    • Financial Reports
    • The Share
    • Ownership Structure
    • Analyst and Media Coverage
    • Financial Calendar
    • Prospectuses
    • Press Releases
    • Subscribe
    • Certified Adviser

Share

Read more
Initiator Pharma logo
About Initiator Pharma
  • Mission
  • Scientific and Clinical Advisory Board
  • Goals, strategy and business model
  • CEO Letter
  • History
Science
  • Pipeline
  • Pudafensine
    • Clinical programs
    • Preclinical program
  • IP2018
    • Clinical programs
    • Preclinical program
  • Therapeutic Areas
    • Erectile Dysfunction
    • Female Sexual Dysfunction
    • Depression
    • Trigeminal Neuralgia
Governance
  • General Meetings
  • Management
  • Board of Directors
  • Auditing
  • Articles of Association
  • Remuneration and incentive program
Investors
  • Investment case
  • Financial Reports
  • The Share
  • Ownership Structure
  • Analyst and Media Coverage
  • Financial Calendar
  • Prospectuses
  • Press Releases
  • Subscribe
  • Certified Adviser
Media
  • Press Releases
  • Event Calendar
  • Subscribe
Contact

Share

Read more
  • Cookies
  • Privacy